Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Fc gamma R-mediated phagocytosis (mmu04666)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
AK053501
KLA  ATP  ATP+KLA
 AK053501 0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130103H07 product:inferred: ADP-ribosylation factor-directed GTPase activating protein isoform b {Mus musculus}, full insert sequence. [AK053501] KLA .85 .71 .60 .70 .76 .70 .64
ATP 1.15 1.25 1.21 1.01 .71 .68 1.09
KLA/ATP .86 .89 .67 .72 .64 .55 .83
Akt1
KLA  ATP  ATP+KLA
 NM_009652 thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] KLA .80 .80 .75 .75 .71 .70 .82
ATP 1.00 1.02 .76 .85 .76 .68 .84
KLA/ATP .82 .80 .64 .68 .67 .61 .72
Akt2
KLA  ATP  ATP+KLA
 NM_007434 thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] KLA 1.45 1.49 1.81 1.61 1.83 1.17 .92
ATP 1.12 1.12 1.00 1.28 1.20 .94 1.06
KLA/ATP 1.48 1.70 1.69 1.58 1.57 1.32 1.27
Akt3
KLA  ATP  ATP+KLA
 NM_011785 thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] KLA 3.42 3.45 5.31 5.16 4.65 3.80 2.12
ATP 1.12 1.22 1.10 1.37 1.02 1.11 1.56
KLA/ATP 3.72 4.17 4.62 4.64 2.74 2.05 3.82
Amph
KLA  ATP  ATP+KLA
 AK047144 10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:B930026D14 product:similar to MYC BOX DEPENDENT INTERACTING PROTEIN 1 (BRIDGING INTEGRATOR 1) (AMPHIPHYSIN-LIKE PROTEIN) (AMPHIPHYSIN II) [Rattus norvegicus], full KLA .96 .98 .94 .99 1.06 1.02 1.04
ATP 1.00 1.02 1.06 .99 .98 1.06 1.00
KLA/ATP .97 .94 1.08 1.02 1.00 1.04 .97
Amph
KLA  ATP  ATP+KLA
 NM_175007 amphiphysin (Amph), mRNA [NM_175007] KLA .97 1.04 1.04 1.04 1.04 .99 1.02
ATP 1.01 1.02 1.00 .98 .95 1.01 1.02
KLA/ATP 1.00 1.08 .96 1.04 .97 1.00 .94
Arf6
KLA  ATP  ATP+KLA
 NM_007481 ADP-ribosylation factor 6 (Arf6), mRNA [NM_007481] KLA .99 1.01 1.19 1.22 1.41 1.33 1.13
ATP 1.02 1.12 1.06 1.43 1.16 1.12 1.37
KLA/ATP 1.04 1.01 .91 1.32 1.16 1.32 1.52
Arpc1a
KLA  ATP  ATP+KLA
 NM_019767 actin related protein 2/3 complex, subunit 1A (Arpc1a), mRNA [NM_019767] KLA .80 .78 .73 .79 .90 1.02 .97
ATP 1.01 1.07 .93 .86 .83 1.14 1.15
KLA/ATP .77 .74 .64 .64 .77 1.13 1.51
Arpc1b
KLA  ATP  ATP+KLA
 NM_023142 actin related protein 2/3 complex, subunit 1B (Arpc1b), mRNA [NM_023142] KLA .85 .86 .81 .83 .92 .93 1.03
ATP 1.03 .98 .86 .79 .84 .85 .91
KLA/ATP .88 .84 .83 .73 .71 .70 .63
Arpc2
KLA  ATP  ATP+KLA
 NM_029711 actin related protein 2/3 complex, subunit 2 (Arpc2), mRNA [NM_029711] KLA .88 .89 1.05 .92 1.18 1.31 1.21
ATP 1.20 1.18 .86 .94 .85 .48 .87
KLA/ATP 1.04 1.05 .78 .87 .70 .60 .92
Arpc3
KLA  ATP  ATP+KLA
 NM_019824 actin related protein 2/3 complex, subunit 3 (Arpc3), mRNA [NM_019824] KLA .93 .96 1.05 .95 1.07 1.09 .80
ATP 1.08 1.05 .95 .99 1.03 1.01 .97
KLA/ATP 1.00 1.02 .99 1.04 1.06 1.21 .99
Arpc4
KLA  ATP  ATP+KLA
 NM_026552 actin related protein 2/3 complex, subunit 4 (Arpc4), mRNA [NM_026552] KLA .75 .81 .83 .73 .94 1.12 1.12
ATP 1.09 1.34 .90 1.52 .98 .63 .89
KLA/ATP .92 .90 .58 1.10 .64 .69 .87
Arpc5
KLA  ATP  ATP+KLA
 NM_026369 actin related protein 2/3 complex, subunit 5 (Arpc5), mRNA [NM_026369] KLA 1.35 1.37 1.44 1.33 1.59 1.84 1.39
ATP .98 1.08 1.01 1.14 .97 .87 1.36
KLA/ATP 1.19 1.30 1.23 1.44 1.13 1.28 1.60
Arpc5l
KLA  ATP  ATP+KLA
 NM_028809 actin related protein 2/3 complex, subunit 5-like (Arpc5l), mRNA [NM_028809] KLA .59 .61 .60 .59 .61 .77 1.02
ATP .92 .92 .99 1.01 .79 .76 1.01
KLA/ATP .58 .60 .64 .59 .66 .71 .98
Cdc42
KLA  ATP  ATP+KLA
 NM_009861 cell division cycle 42 homolog (S. cerevisiae) (Cdc42), mRNA [NM_009861] KLA 1.04 1.01 1.02 1.04 1.12 1.21 1.12
ATP 1.07 1.10 1.04 1.06 1.02 .95 1.14
KLA/ATP .94 1.04 1.01 .97 .95 1.02 1.25
Cfl1
KLA  ATP  ATP+KLA
 NM_007687 cofilin 1, non-muscle (Cfl1), mRNA [NM_007687] KLA .90 1.01 1.14 .87 1.17 1.17 1.48
ATP 1.24 1.60 .81 1.77 1.07 .88 1.27
KLA/ATP 1.33 1.48 .50 1.58 .71 .93 1.31
Cfl2
KLA  ATP  ATP+KLA
 NM_007688 cofilin 2, muscle (Cfl2), mRNA [NM_007688] KLA .62 .65 .74 .97 .99 .97 1.03
ATP .57 .49 .50 .49 .94 .97 .76
KLA/ATP .47 .41 .44 .58 1.02 1.05 .93
Crk
KLA  ATP  ATP+KLA
 NM_133656 v-crk sarcoma virus CT10 oncogene homolog (avian) (Crk), mRNA [NM_133656] KLA 1.29 1.32 1.41 1.38 1.75 1.59 1.52
ATP 1.08 1.17 1.01 .93 1.27 2.11 1.70
KLA/ATP 1.37 1.49 1.14 1.09 1.21 1.69 2.32
Crkl
KLA  ATP  ATP+KLA
 NM_007764 v-crk sarcoma virus CT10 oncogene homolog (avian)-like (Crkl), mRNA [NM_007764] KLA 1.85 1.97 2.08 1.73 1.66 1.64 1.36
ATP .97 .94 .78 .74 1.46 1.89 1.46
KLA/ATP 1.92 1.88 1.18 1.44 1.67 2.65 2.72
Ddef1
KLA  ATP  ATP+KLA
 AK147689 14 days pregnant adult female placenta cDNA, RIKEN full-length enriched library, clone:M5C1108F01 product:development and differentiation enhancing, full insert sequence [AK147689] KLA 1.39 1.17 .77 .40 .35 .37 .43
ATP 1.06 1.02 .78 .58 .32 .20 .83
KLA/ATP 1.17 1.12 .69 .57 .21 .13 .29
Ddef1
KLA  ATP  ATP+KLA
 NM_010026 development and differentiation enhancing (Ddef1), mRNA [NM_010026] KLA 1.79 1.52 1.41 .70 .52 .56 .58
ATP 1.24 1.13 .78 .83 .57 .40 1.63
KLA/ATP 1.95 1.71 1.07 1.01 .53 .24 1.05
Ddef2
KLA  ATP  ATP+KLA
 NM_001004364 development and differentiation enhancing factor 2 (Ddef2), transcript variant 2, mRNA [NM_001004364] KLA .54 .52 .48 .47 .32 .35 .35
ATP 1.01 1.05 .79 .67 .35 .53 .68
KLA/ATP .51 .52 .53 .45 .31 .40 .40
Ddefl1
KLA  ATP  ATP+KLA
 AK035099 12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library, clone:9430088F20 product:hypothetical Ankyrin repeat profile/Serine-rich region/Ankyrin-repeat/Ankyrin repeat region circular profil KLA 3.72 3.96 4.21 2.49 1.30 1.10 1.05
ATP .99 .94 1.10 1.07 .99 1.03 1.04
KLA/ATP 3.11 4.46 3.60 2.53 1.62 1.34 1.08
Dnm2
KLA  ATP  ATP+KLA
 NM_001039520 dynamin 2 (Dnm2), mRNA [NM_001039520] KLA 1.00 1.03 1.14 1.01 1.29 1.47 1.30
ATP 1.11 1.31 .93 1.41 1.04 .90 1.53
KLA/ATP 1.26 1.23 .87 1.41 .86 .98 1.86
Dock2
KLA  ATP  ATP+KLA
 NM_033374 dedicator of cyto-kinesis 2 (Dock2), mRNA [NM_033374] KLA .97 .95 1.03 .73 .86 .81 1.01
ATP 1.05 1.18 .90 1.28 .77 .26 .73
KLA/ATP 1.07 1.12 .78 1.14 .54 .36 .78
EG629860
KLA  ATP  ATP+KLA
 M17953 gb|Mouse Ig rearranged H-chain V-region mRNA VJ1 [M17953] KLA .96 1.05 1.03 1.08 1.08 1.02 .98
ATP .97 .99 1.05 1.10 .95 .94 .91
KLA/ATP .96 .94 .97 1.04 .97 1.01 .89
Fcgr1
KLA  ATP  ATP+KLA
 AF143181 strain AB/H (Biozzi) high affinity immunoglobulin gamma Fc receptor I (Fcgr1) mRNA, Fcgr1-d allele, complete cds. [AF143181] KLA 4.27 4.21 5.59 6.14 8.13 9.76 10.98
ATP 1.23 1.12 1.08 1.36 1.09 2.09 11.81
KLA/ATP 4.56 4.93 4.95 5.88 6.66 9.64 23.09
Fcgr1
KLA  ATP  ATP+KLA
 NM_010186 Fc receptor, IgG, high affinity I (Fcgr1), mRNA [NM_010186] KLA 4.31 4.37 4.70 5.97 6.59 10.06 8.67
ATP 1.01 .88 1.16 .89 .90 2.15 9.23
KLA/ATP 4.01 4.10 5.52 4.54 6.31 9.24 15.83
Fcgr2b
KLA  ATP  ATP+KLA
 NM_001077189 Fc receptor, IgG, low affinity IIb (Fcgr2b), transcript variant 1, mRNA [NM_001077189] KLA 16.93 17.57 21.75 27.43 34.13 31.88 5.70
ATP 1.11 1.09 1.17 1.46 2.81 11.26 1.92
KLA/ATP 16.51 17.91 23.67 29.22 22.67 25.33 9.54
Fcgr2b
KLA  ATP  ATP+KLA
 NM_010187 Fc receptor, IgG, low affinity IIb (Fcgr2b), transcript variant 2, mRNA [NM_010187] KLA 11.41 11.67 14.06 15.47 17.28 18.63 4.69
ATP 1.05 1.06 1.18 1.57 2.27 8.97 2.10
KLA/ATP 10.98 12.01 15.03 18.38 15.15 16.00 8.33
Gab2
KLA  ATP  ATP+KLA
 NM_010248 growth factor receptor bound protein 2-associated protein 2 (Gab2), mRNA [NM_010248] KLA 1.01 1.04 1.04 1.02 1.12 1.16 1.14
ATP 1.02 1.06 1.00 1.13 1.16 1.19 1.23
KLA/ATP 1.06 1.05 1.03 1.02 1.03 1.04 1.29
Gsn
KLA  ATP  ATP+KLA
 NM_146120 gelsolin (Gsn), mRNA [NM_146120] KLA .71 .69 .70 .61 .47 .39 .32
ATP .99 .86 .95 .65 .61 .44 .46
KLA/ATP .71 .80 .61 .48 .43 .32 .20
Hck
KLA  ATP  ATP+KLA
 NM_010407 hemopoietic cell kinase (Hck), mRNA [NM_010407] KLA 4.59 4.25 4.84 6.31 7.85 6.43 4.34
ATP 1.05 1.02 .84 .84 1.12 1.82 1.55
KLA/ATP 4.31 4.18 4.53 3.92 4.14 3.10 4.00
Igh-VJ55
8
KLA  ATP  ATP+KLA
 AY547436 immunoglobulin heavy chain VDJ region mRNA, partial cds [AY547436] KLA 1.06 1.05 1.01 .93 1.03 .96 .93
ATP .99 1.00 1.06 .95 .96 1.06 1.05
KLA/ATP .98 .94 1.07 .95 .97 .99 1.02
Igh-VJ55
8
KLA  ATP  ATP+KLA
 CA578712 gb|K0727F04-5N NIA Mouse Hematopoietic Stem Cell (Lin- [CA578712] KLA .99 .94 1.01 1.10 .93 .97 .92
ATP .93 1.04 1.01 .98 1.05 .96 .95
KLA/ATP .99 .95 .95 .98 1.02 .98 .95
Igh-VJ55
8
KLA  ATP  ATP+KLA
 ENSMUST00000103412 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHA] [ENSMUST00000103412] KLA 1.01 .97 1.20 1.01 .98 1.44 1.24
ATP .99 .98 1.07 1.03 1.00 1.01 1.21
KLA/ATP .99 1.02 .96 1.03 .97 1.13 1.30
Igh-VJ55
8
KLA  ATP  ATP+KLA
 ENSMUST00000103413 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHE] [ENSMUST00000103413] KLA 1.00 .99 1.06 1.06 .99 1.03 1.02
ATP 1.08 1.06 1.06 1.06 1.02 1.06 .95
KLA/ATP 1.00 1.04 1.09 1.02 1.06 1.02 .95
Igh-VJ55
8
KLA  ATP  ATP+KLA
 U39781 J558+ IgM heavy chain mRNA, hybridoma clone ME2B7, partial cds. [U39781] KLA .93 .89 .98 .97 1.03 1.00 .94
ATP 1.04 1.02 1.08 .94 .93 .90 .79
KLA/ATP .88 .89 .97 .93 .88 .92 .82
Inpp5d
KLA  ATP  ATP+KLA
 NM_010566 inositol polyphosphate-5-phosphatase D (Inpp5d), transcript variant 1, mRNA [NM_010566] KLA .17 .15 .13 .20 .56 1.17 .81
ATP 1.09 1.05 .86 .70 .37 .42 1.25
KLA/ATP .18 .15 .14 .12 .17 .37 1.19
Inppl1
KLA  ATP  ATP+KLA
 NM_010567 inositol polyphosphate phosphatase-like 1 (Inppl1), transcript variant 1, mRNA [NM_010567] KLA .82 .80 .73 .81 .79 .72 .94
ATP 1.05 1.04 .69 .58 .56 .87 .98
KLA/ATP .90 .83 .58 .46 .87 1.07 1.34
Lat
KLA  ATP  ATP+KLA
 NM_010689 linker for activation of T cells (Lat), mRNA [NM_010689] KLA .91 .95 .94 .87 .76 .63 .48
ATP .97 .99 1.01 1.50 1.59 1.49 1.00
KLA/ATP .91 1.04 .93 1.15 1.11 .96 .65
Limk1
KLA  ATP  ATP+KLA
 NM_010717 LIM-domain containing, protein kinase (Limk1), mRNA [NM_010717] KLA .56 .57 .51 .67 .79 .93 .98
ATP .95 .88 .92 .75 1.01 .86 .88
KLA/ATP .53 .52 .56 .49 .90 .84 .51
Limk2
KLA  ATP  ATP+KLA
 NM_010718 LIM motif-containing protein kinase 2 (Limk2), transcript variant 1, mRNA [NM_010718] KLA .69 .73 .79 .92 1.12 1.18 .97
ATP 1.09 1.05 1.02 .90 .70 .93 1.15
KLA/ATP .78 .76 .77 .69 .71 1.07 1.42
Lyn
KLA  ATP  ATP+KLA
 NM_010747 Yamaguchi sarcoma viral (v-yes-1) oncogene homolog (Lyn), transcript variant 2, mRNA [NM_010747] KLA 2.48 2.80 3.76 3.81 5.30 4.57 2.46
ATP 1.06 1.18 .82 .97 .74 1.45 1.21
KLA/ATP 2.82 3.16 2.24 2.87 1.73 1.80 2.63
Map2k1
KLA  ATP  ATP+KLA
 NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Marcks
KLA  ATP  ATP+KLA
 NM_008538 myristoylated alanine rich protein kinase C substrate (Marcks), mRNA [NM_008538] KLA 5.22 4.64 5.16 5.22 4.23 3.04 2.24
ATP .92 .90 .87 .95 3.05 3.49 1.47
KLA/ATP 4.38 4.30 4.63 4.01 4.51 3.65 3.44
Marcksl1
KLA  ATP  ATP+KLA
 NM_010807 MARCKS-like 1 (Marcksl1), mRNA [NM_010807] KLA 11.17 9.95 10.63 9.53 10.67 5.90 3.84
ATP 1.42 1.91 1.55 5.70 4.10 2.89 .97
KLA/ATP 12.20 13.11 7.97 14.47 9.03 5.78 6.06
Mm.21312
8
KLA  ATP  ATP+KLA
 141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.25381
9
KLA  ATP  ATP+KLA
 118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.27682
6
KLA  ATP  ATP+KLA
 126513132 Unknown KLA .74 .69 .83 .96 .93 .97 1.21
ATP .71 .66 .60 .75 .88 .90 .79
KLA/ATP .63 .57 .63 .72 .89 .99 .90
Mm.28873
KLA  ATP  ATP+KLA
 110431340 Unknown KLA .79 .72 .69 .71 .44 .32 .37
ATP .89 .88 1.17 .98 1.11 .98 .73
KLA/ATP .67 .72 .87 .74 .75 .53 .30
Mm.35894
6
KLA  ATP  ATP+KLA
 147907211 Unknown KLA .47 .50 .47 .51 .32 .36 .34
ATP 1.03 .98 .91 .66 .35 .55 .72
KLA/ATP .46 .47 .53 .48 .33 .41 .41
Mm.37161
0
KLA  ATP  ATP+KLA
 118130576 Unknown KLA .76 .74 .66 .81 .74 1.00 .92
ATP .95 .85 1.03 .71 .79 1.32 1.10
KLA/ATP .69 .70 .67 .53 .84 1.50 1.48
Mm.42529
6
KLA  ATP  ATP+KLA
 170172552 Unknown KLA 1.51 1.59 1.64 1.57 1.87 1.40 1.91
ATP 1.02 1.04 .77 .91 .52 .49 1.04
KLA/ATP 1.63 1.53 1.11 1.32 .80 .69 1.23
Mm.44463
KLA  ATP  ATP+KLA
 118129851 Unknown KLA 1.01 .98 .97 1.02 .93 1.06 1.05
ATP .97 1.01 1.04 1.06 1.02 1.08 .97
KLA/ATP 1.02 1.06 .95 1.04 1.09 1.14 1.03
Myo10
KLA  ATP  ATP+KLA
 AK089482 B6-derived CD11 +ve dendritic cells cDNA, RIKEN full-length enriched library, clone:F730038D06 product:hypothetical protein, full insert sequence. [AK089482] KLA 1.21 1.09 1.19 1.04 1.11 1.26 1.34
ATP 1.01 .96 1.26 1.32 1.22 1.20 1.10
KLA/ATP 1.17 1.15 1.27 1.21 1.06 1.14 1.37
Myo10
KLA  ATP  ATP+KLA
 NM_019472 myosin X (Myo10), mRNA [NM_019472] KLA 3.54 3.54 2.96 2.33 1.61 1.36 1.34
ATP 1.04 1.01 .60 .79 .98 1.03 1.17
KLA/ATP 3.88 3.56 1.75 1.75 .97 .86 2.22
Ncf1
KLA  ATP  ATP+KLA
 NM_010876 neutrophil cytosolic factor 1 (Ncf1), mRNA [NM_010876] KLA 1.62 1.71 1.81 1.70 1.99 1.64 2.07
ATP 1.02 1.06 .78 1.02 .64 .56 1.08
KLA/ATP 1.87 1.81 1.22 1.73 1.00 .80 1.49
Pak1
KLA  ATP  ATP+KLA
 NM_011035 p21 (CDKN1A)-activated kinase 1 (Pak1), mRNA [NM_011035] KLA .72 .77 .79 .71 .67 .73 .95
ATP 1.10 1.07 .99 1.15 1.27 .62 .51
KLA/ATP .85 .83 .73 .76 .76 .55 .33
Pik3ca
KLA  ATP  ATP+KLA
 ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
 NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
 NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
 NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
 U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
 NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
 NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
 NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
 NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
 NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Pip5k1a
KLA  ATP  ATP+KLA
 NM_008847 phosphatidylinositol-4-phosphate 5-kinase, type 1 alpha (Pip5k1a), mRNA [NM_008847] KLA 1.99 1.84 1.66 1.49 1.49 1.37 1.57
ATP 1.05 1.06 .89 1.54 4.20 2.72 1.58
KLA/ATP 1.95 1.90 1.55 1.60 3.26 2.64 2.25
Pip5k1b
KLA  ATP  ATP+KLA
 NM_008846 phosphatidylinositol-4-phosphate 5-kinase, type 1 beta (Pip5k1b), mRNA [NM_008846] KLA 1.24 1.35 1.11 .92 .57 .72 .86
ATP .86 1.00 .96 1.15 .85 .74 .89
KLA/ATP 1.20 1.22 .97 1.00 .78 .76 1.06
Pip5k1c
KLA  ATP  ATP+KLA
 BC094665 phosphatidylinositol-4-phosphate 5-kinase, type 1 gamma, mRNA (cDNA clone MGC:102155 IMAGE:30356181), complete cds [BC094665] KLA .82 .90 .90 .70 .96 .86 1.21
ATP 1.19 1.45 .92 1.64 1.17 .83 1.33
KLA/ATP .97 1.21 .66 1.20 .91 .92 1.69
Pip5k1c
KLA  ATP  ATP+KLA
 NM_008844 phosphatidylinositol-4-phosphate 5-kinase, type 1 gamma (Pip5k1c), mRNA [NM_008844] KLA 1.40 1.36 1.38 1.39 1.30 1.30 1.27
ATP 1.01 1.16 1.12 1.46 1.38 1.35 1.21
KLA/ATP 1.39 1.44 1.44 1.64 1.41 1.45 1.53
Pla2g4a
KLA  ATP  ATP+KLA
 NM_008869 phospholipase A2, group IVA (cytosolic, calcium-dependent) (Pla2g4a), mRNA [NM_008869] KLA 3.93 4.49 4.86 6.40 6.44 3.10 1.68
ATP 1.13 1.36 1.27 1.30 1.02 5.37 1.47
KLA/ATP 3.64 4.45 4.76 7.11 2.96 4.08 2.60
Pla2g4e
KLA  ATP  ATP+KLA
 AK049063 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230096D22 product:hypothetical Lysophospholipase catalytic domain containing protein, full insert sequence. [AK049063] KLA 1.03 1.09 1.01 1.01 1.06 .94 1.05
ATP 1.03 1.00 1.06 1.01 .96 1.05 1.05
KLA/ATP .98 1.00 1.01 .98 1.03 .95 1.01
Pla2g4e
KLA  ATP  ATP+KLA
 NM_177845 phospholipase A2, group IVE (Pla2g4e), mRNA [NM_177845] KLA .97 .95 1.01 .97 1.02 1.03 1.05
ATP .98 .99 1.00 1.10 .98 1.00 1.02
KLA/ATP 1.05 .93 .96 1.03 1.08 1.05 .99
Pla2g6
KLA  ATP  ATP+KLA
 NM_016915 phospholipase A2, group VI (Pla2g6), mRNA [NM_016915] KLA .60 .59 .56 .60 .94 1.31 1.59
ATP 1.10 1.14 .95 1.05 1.06 1.13 1.14
KLA/ATP .63 .56 .54 .56 .71 .97 1.55
Plcg2
KLA  ATP  ATP+KLA
 NM_172285 phospholipase C, gamma 2 (Plcg2), mRNA [NM_172285] KLA .76 .74 .68 .66 .71 .92 .95
ATP .96 .90 .95 .87 .81 .79 .91
KLA/ATP .76 .71 .69 .62 .72 .78 .68
Pld1
KLA  ATP  ATP+KLA
 NM_008875 phospholipase D1 (Pld1), mRNA [NM_008875] KLA .71 .73 .67 .73 .88 .96 1.25
ATP .99 .88 .73 .68 .45 1.23 1.12
KLA/ATP .70 .67 .58 .59 .48 .91 1.48
Pld2
KLA  ATP  ATP+KLA
 NM_008876 phospholipase D2 (Pld2), mRNA [NM_008876] KLA .51 .54 .48 .51 .73 .79 1.02
ATP 1.06 1.10 .88 1.03 1.04 1.29 1.00
KLA/ATP .63 .52 .40 .57 .65 1.03 1.35
Ppap2a
KLA  ATP  ATP+KLA
 NM_008903 phosphatidic acid phosphatase 2a (Ppap2a), transcript variant 2, mRNA [NM_008903] KLA 2.62 2.86 4.01 5.61 7.84 10.88 16.35
ATP 1.01 1.02 1.09 1.28 1.27 2.38 1.44
KLA/ATP 2.78 2.78 2.99 3.43 2.85 3.59 6.59
Ppap2b
KLA  ATP  ATP+KLA
 NM_080555 phosphatidic acid phosphatase type 2B (Ppap2b), mRNA [NM_080555] KLA 2.73 2.72 2.65 2.39 1.07 1.48 3.26
ATP .99 .97 1.60 2.76 18.64 27.23 9.19
KLA/ATP 2.69 2.80 4.36 4.20 14.33 15.32 17.91
Ppap2c
KLA  ATP  ATP+KLA
 NM_015817 phosphatidic acid phosphatase type 2c (Ppap2c), mRNA [NM_015817] KLA .94 .88 .91 .79 .65 .46 .51
ATP 1.01 1.03 1.00 1.12 1.24 .90 .83
KLA/ATP .95 .93 .87 .95 .79 .63 .43
Prkca
KLA  ATP  ATP+KLA
 NM_011101 protein kinase C, alpha (Prkca), mRNA [NM_011101] KLA 1.00 .96 .94 .95 .95 .89 .96
ATP 1.00 1.03 .91 .94 .82 .87 1.13
KLA/ATP 1.02 .95 .91 .86 .78 .84 .94
Prkcb1
KLA  ATP  ATP+KLA
 NM_008855 protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855] KLA .92 .95 .93 .78 .77 1.08 1.83
ATP 1.03 1.12 1.09 1.23 .90 2.08 .96
KLA/ATP .98 .99 .82 .89 .62 1.01 1.08
Prkcc
KLA  ATP  ATP+KLA
 NM_011102 protein kinase C, gamma (Prkcc), mRNA [NM_011102] KLA 1.02 1.04 1.11 1.04 .96 1.02 1.05
ATP .98 .98 1.05 1.03 1.08 .96 .95
KLA/ATP 1.21 1.16 1.09 1.07 1.04 .98 .93
Prkcd
KLA  ATP  ATP+KLA
 NM_011103 protein kinase C, delta (Prkcd), mRNA [NM_011103] KLA 1.72 1.84 1.90 1.68 2.01 1.61 1.64
ATP 1.00 1.03 .68 .81 1.38 1.26 .98
KLA/ATP 1.77 1.79 1.16 1.19 1.33 1.25 1.56
Prkce
KLA  ATP  ATP+KLA
 AK017901 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830406C15 product:unclassifiable, full insert sequence. [AK017901] KLA 1.63 1.44 1.95 2.09 1.96 1.34 1.56
ATP .99 .83 .85 .78 .85 2.44 1.47
KLA/ATP 1.36 1.45 1.44 1.23 1.30 2.39 2.29
Prkce
KLA  ATP  ATP+KLA
 AK042994 7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730046G04 product:protein kinase C, epsilon, full insert sequence. [AK042994] KLA 1.01 1.07 1.03 1.03 1.04 1.00 1.06
ATP .99 1.09 1.08 1.05 1.02 1.06 1.07
KLA/ATP 1.00 .90 1.06 1.14 1.10 1.08 1.09
Ptprc
KLA  ATP  ATP+KLA
 AK088215 2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430007G18 product:protein tyrosine phosphatase, receptor type, C, full insert sequence. [AK088215] KLA 2.15 1.93 2.11 1.83 2.08 1.72 1.51
ATP .95 .84 .65 .50 1.79 .82 .77
KLA/ATP 2.01 1.68 1.50 .80 1.16 .73 1.14
Ptprc
KLA  ATP  ATP+KLA
 NM_011210 protein tyrosine phosphatase, receptor type, C (Ptprc), transcript variant 2, mRNA [NM_011210] KLA 2.06 2.00 2.21 2.29 2.20 1.90 1.86
ATP 1.02 .99 1.23 .82 1.01 1.68 .86
KLA/ATP 1.89 2.00 2.40 1.52 1.24 1.01 1.20
Rac1
KLA  ATP  ATP+KLA
 NM_009007 RAS-related C3 botulinum substrate 1 (Rac1), mRNA [NM_009007] KLA 1.02 1.01 1.02 .99 1.03 1.15 1.08
ATP .99 1.15 1.01 1.27 1.06 1.20 1.06
KLA/ATP 1.00 1.04 .88 1.16 .91 1.21 1.38
Rac2
KLA  ATP  ATP+KLA
 NM_009008 RAS-related C3 botulinum substrate 2 (Rac2), mRNA [NM_009008] KLA 1.55 1.68 1.86 2.15 3.36 3.59 3.74
ATP 1.13 1.16 .74 .99 .84 .91 1.66
KLA/ATP 1.59 1.71 1.19 1.56 1.21 1.60 3.48
Raf1
KLA  ATP  ATP+KLA
 AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
 NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Rps6kb1
KLA  ATP  ATP+KLA
 NM_001114334 ribosomal protein S6 kinase, polypeptide 1 (Rps6kb1), transcript variant 1, mRNA [NM_001114334] KLA .99 1.00 .90 .89 .99 .99 .92
ATP 1.01 .96 1.00 .79 1.36 1.19 .72
KLA/ATP 1.08 .99 .93 .92 1.18 .90 .56
Rps6kb1
KLA  ATP  ATP+KLA
 NM_028259 ribosomal protein S6 kinase, polypeptide 1 (Rps6kb1), transcript variant 2, mRNA [NM_028259] KLA 1.01 .93 1.07 1.04 .99 .99 .98
ATP 1.09 1.05 1.00 1.01 1.08 1.03 1.03
KLA/ATP 1.07 1.04 .94 .98 1.03 1.05 1.05
Rps6kb2
KLA  ATP  ATP+KLA
 AK090093 kidney CCL-142 RAG cDNA, RIKEN full-length enriched library, clone:G430107K15 product:ribosomal protein S6 kinase, 70kD, polypeptide 2, full insert sequence [AK090093] KLA .97 1.01 .98 .97 .98 1.04 1.07
ATP 1.00 1.08 1.06 1.09 1.11 1.06 1.03
KLA/ATP 1.05 .96 .86 1.03 1.40 1.07 .99
Rps6kb2
KLA  ATP  ATP+KLA
 NM_021485 ribosomal protein S6 kinase, polypeptide 2 (Rps6kb2), mRNA [NM_021485] KLA 1.36 1.40 1.45 1.40 1.63 1.57 1.46
ATP 1.08 1.19 .97 1.15 .90 .99 1.34
KLA/ATP 1.44 1.55 1.09 1.39 1.00 1.12 1.77
Scin
KLA  ATP  ATP+KLA
 NM_009132 scinderin (Scin), mRNA [NM_009132] KLA 1.23 1.20 1.11 .94 .94 .89 1.22
ATP .99 .96 1.22 1.23 1.62 1.21 1.65
KLA/ATP 1.08 1.26 1.18 1.35 2.00 1.38 1.58
Sphk1
KLA  ATP  ATP+KLA
 NM_025367 sphingosine kinase 1 (Sphk1), transcript variant 2, mRNA [NM_025367] KLA 2.61 2.50 2.04 1.71 1.19 .91 .74
ATP .94 1.00 2.06 8.09 16.52 12.59 3.53
KLA/ATP 2.64 2.81 3.50 8.13 23.71 16.46 2.22
Sphk2
KLA  ATP  ATP+KLA
 NM_020011 sphingosine kinase 2 (Sphk2), transcript variant 2, mRNA [NM_020011] KLA .64 .74 1.05 1.47 2.15 1.84 1.67
ATP 1.10 1.02 .57 .54 .49 1.29 2.15
KLA/ATP .78 .64 .43 .56 .86 1.90 3.74
Syk
KLA  ATP  ATP+KLA
 NM_011518 spleen tyrosine kinase (Syk), mRNA [NM_011518] KLA 2.48 2.59 2.57 2.26 3.29 3.75 3.19
ATP .96 .85 .59 1.01 2.80 3.77 2.11
KLA/ATP 2.56 2.09 1.16 1.35 2.50 4.33 5.10
Vasp
KLA  ATP  ATP+KLA
 NM_009499 vasodilator-stimulated phosphoprotein (Vasp), mRNA [NM_009499] KLA 4.52 4.78 4.94 4.54 5.95 5.17 5.17
ATP 1.11 1.31 .93 1.41 1.48 1.45 1.14
KLA/ATP 4.65 5.51 4.13 5.08 2.96 2.18 4.11
Vav1
KLA  ATP  ATP+KLA
 NM_011691 vav 1 oncogene (Vav1), mRNA [NM_011691] KLA .79 .83 .98 1.17 1.97 2.42 2.26
ATP 1.06 1.02 .88 1.01 1.34 .82 1.36
KLA/ATP .88 .85 .73 .78 1.25 1.47 2.17
Vav2
KLA  ATP  ATP+KLA
 BC053060 vav 2 oncogene, mRNA (cDNA clone MGC:62363 IMAGE:5704852), complete cds [BC053060] KLA .73 .58 .55 1.16 .76 1.35 1.75
ATP .99 .89 .79 .82 .67 .85 1.09
KLA/ATP .64 .63 .61 .65 .66 .80 1.23
Vav2
KLA  ATP  ATP+KLA
 NM_009500 vav 2 oncogene (Vav2), mRNA [NM_009500] KLA .98 1.05 .98 .99 1.02 1.36 1.43
ATP 1.07 1.06 .96 1.01 .89 .95 1.08
KLA/ATP 1.04 1.05 .98 1.03 .88 .99 1.13
Vav3
KLA  ATP  ATP+KLA
 NM_020505 vav 3 oncogene (Vav3), transcript variant 1, mRNA [NM_020505] KLA .95 .94 .86 .87 .82 .66 .56
ATP 1.06 1.09 .81 1.05 .80 .75 .85
KLA/ATP 1.00 .84 .62 .85 .74 .56 .74
Was
KLA  ATP  ATP+KLA
 NM_009515 Wiskott-Aldrich syndrome homolog (human) (Was), mRNA [NM_009515] KLA .66 .67 .64 .65 .88 1.08 1.09
ATP 1.08 1.11 .87 1.23 .77 .51 .90
KLA/ATP .76 .70 .44 .83 .49 .61 .91
Wasf1
KLA  ATP  ATP+KLA
 NM_031877 WASP family 1 (Wasf1), mRNA [NM_031877] KLA .75 .69 .77 .81 .69 .66 .54
ATP 1.01 .97 .93 .98 .70 .66 .97
KLA/ATP .75 .73 .80 .79 .73 .67 .56
Wasf2
KLA  ATP  ATP+KLA
 AK150140 bone marrow macrophage cDNA, RIKEN full-length enriched library, clone:G530136J12 product:WAS protein family, member 2, full insert sequence [AK150140] KLA .58 .52 .52 .83 1.06 1.17 .91
ATP .97 .89 .93 .57 .72 .72 .86
KLA/ATP .55 .45 .56 .36 .45 .65 1.08
Wasf2
KLA  ATP  ATP+KLA
 NM_153423 WAS protein family, member 2 (Wasf2), mRNA [NM_153423] KLA .67 .75 .66 1.01 1.31 1.28 1.19
ATP 1.05 1.10 .82 .81 .82 .68 .92
KLA/ATP .75 .76 .73 .57 .61 .77 1.16
Wasf3
KLA  ATP  ATP+KLA
 NM_145155 WAS protein family, member 3 (Wasf3), mRNA [NM_145155] KLA .94 .95 1.06 .95 1.00 1.10 1.07
ATP .95 .96 .93 1.01 1.01 1.03 1.08
KLA/ATP 1.01 .91 .96 .95 .96 1.03 1.05
Wasl
KLA  ATP  ATP+KLA
 NM_028459 Wiskott-Aldrich syndrome-like (human) (Wasl), mRNA [NM_028459] KLA .88 .89 .96 .85 .97 1.08 1.14
ATP 1.08 .99 .71 .76 1.71 .91 .99
KLA/ATP .96 .84 .72 .84 1.51 .91 1.24